Source: BioSig Technologies, Inc.
BioSig Technologies, Inc. (OTCQB: BSGM),
a medical device company developing a proprietary biomedical signal
processing platform designed to address an unmet technology need for the
$4.6 billion electrophysiology (EP) marketplace, today announced that
Mr. Steven (Steve) Chaussy will be joining the company to serve in the
role of Chief Financial Officer.
Mr. Chaussy brings over 30
years of financial and operating experience to the Company. Prior to
joining BioSig Technologies, Mr. Chaussy has been the sole proprietor of
Anna & Co., Inc., a consulting company that offers financial and
accounting services to small publicly traded companies. Mr. Chaussy has
an extensive entrepreneurial growth and development background learned
from working for Penske Truck Leasing Co., L.P., a subsidiary of Penske
Corporation, where his improvements of management and reporting tools
have allowed the company to double in size. During his career, Mr.
Chaussy also served as Chief Financial Officer to a number of private
and public companies. The systems introduced by Mr. Chaussy have been
key drivers of profitability and development of international business
lines. Mr. Chaussy is a CPA and received his degree in Accounting from
Virginia Polytechnic Institute and State University.
In his role
as CFO, Mr Chaussy will be responsible for ensuring the financial
organization required to support the Company’s aggressive growth
strategy while establishing a strong foundation for long-term progress.
"Steve
has been supporting BioSig from the very beginning of our journey. As
we step up our efforts towards commercialization, we needed a highly
experienced, full-time CFO with the strong expertise in supporting
emerging growth companies and successfully managing rapidly developing
environments,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig
Technologies, Inc. “Steve’s ability to navigate complex markets is a
definite value-add in both our pre-commercial activities and future
growth of our organization.”
“I am both honored and excited to
be joining the BioSig team at such a key point in their trajectory,”
said Steven Chaussy. “I am impressed with the company current assets,
management team and near-term commercialization prospects. I look
forward to contributing to the future success of the Company.”
About BioSig Technologies
BioSig Technologies is a medical device company developing a
proprietary biomedical signal processing technology designed to improve
the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com).
Led by a proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to
commercialize its PURE EP(TM) System. The technology has been developed
to address an unmet need in a large and growing market.
The
Company’s first product, PURE EP(TM) System, is a novel cardiac signal
acquisition and display system which is engineered to assist
electrophysiologists in clinical decision making during procedures to
diagnose and treat patients with abnormal heart rates and rhythms.
BioSig’s main goal is to deliver technology to improve upon catheter
ablation treatments for the prevalent and deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with
Minnetronix on technology development and is working toward FDA 510(k)
clearance for the PURE EP System.
No comments:
Post a Comment